Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

"In March, our production saw a 17% month-over-month increase in blocks won, even as global hashrate and mining difficulty grew," said Fred Thiel, MARA's chairman and CEO. "Our bitcoin holdings ...

Glucotrack (GCTK) announced an agreement with OneTwo Analytics AB. Through this collaboration, Glucotrack will leverage next-generation ...

Venus Concept VERO shares fell 17.9% to $2.15 during Tuesday's after-market session. The market value of their outstanding shares is at $1.4 million. As per the press release, Q4 earnings came out ...

Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this ...

Revenue increased 23.9% year over year to $379.8 million in FY 2024 Record quarterly revenue of $113.4 million, up 8.4% year over year in Q4 2024 Gross margin increased from 18.7% to 31.5%, a 12.8 ...

Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption ...